Dr. Heinemann Reviews the FIRE-3 Trial Results
Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.
Volker Heinemann, MD, PhD, a professor of medical oncology at the University of Munich in Munich, Germany, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.
In the trial, the objective response rate (ORR) was comparable between the two treatments (bevacizumab and cetuximab). However, in patients who received at least 3 cycles of treatment and had one imaging procedure after baseline, a 10% ORR benefit was observed in the cetuximab arm, Heinemann notes.
Read more about this study >>>
<<<
